The EMA-approved biosimilar monoclonal antibody Remsima, developed for Crohn’s disease (CD), is likely to result in savings ranging from €76m to €336m over five years across, according to Celltrion Healthcare .

Remsima is a biosimilar of the biologic medicine Remicade (infliximab), its reference medicinal product (RMP).

Presented at the European Crohn’s and Colitis Organisation’s (ECCO) tenth annual congress in Barcelona, Spain, the budget impact analysis demonstrated the five-year savings of the drug in France, Italy, and the UK, based on price discount scenarios tested.

Celltrion vice-president Dr Alex Kudrin said: "The data presented today show the clear cost savings that could be achieved by introducing Remsima for the treatment of Crohn’s disease. Remsima may offer physicians an alternative to other anti-tumour necrosis factor treatments.

The analysis was based on the number of patients eligible for infliximab treatment out of the total population, taking into account annual population growth rate and prevalence of CD in three countries.

"Remsima may offer physicians an alternative to other anti-tumour necrosis factor treatments."

The analysis has been carried out based on the assumption that the ratio of patients receiving infliximab would not change in 2019.

As per the firm’s earlier research, the use of biosimilar monoclonal antibodies (mAbs) is expected to save from €1.8bn to €20.4bn, in between 2007 and 2020.

Remsima is an anti-tumour necrosis factor (anti-TNF) mAb, which reduces inflammation and improves other symptoms of the diseases for which it is indicated.

According to Celltrion, clinical trials of Remsima demonstrated safety and efficacy, compared to its RMP.

Celltrion Healthcare president Dr Stanley Hong said: "By developing Remsima we are giving physicians an additional drug choice for treating people with autoimmune diseases."

Image: High-magnification micrograph of Crohn’s disease. Photo: courtesy of Nephron.